Recombinate: viral safety and final product manufacturing testing and specifications.
作者信息
Lawrence J
机构信息
Baxter Healthcare Corporation, Hyland Division, Corporate Development, Glendale, CA 91203.
出版信息
Ann Hematol. 1994;68 Suppl 3:S21-4. doi: 10.1007/BF01774525.
PMID:8180253
Abstract
摘要
相似文献
1
Recombinate: viral safety and final product manufacturing testing and specifications.
Ann Hematol. 1994;68 Suppl 3:S21-4. doi: 10.1007/BF01774525.
2
The manufacturing process of recombinant factor VIII, recombinate.
Transfus Med Rev. 1992 Oct;6(4):247-51. doi: 10.1016/s0887-7963(92)70175-8.
3
Cell culture and purification process--purity and safety testing.细胞培养与纯化过程——纯度与安全性检测。
Ann Hematol. 1994;68 Suppl 3(Suppl 3):S15-20. doi: 10.1007/BF01774524.
4
Design and operation of a recombinant mammalian cell manufacturing process for rFVIII.
Ann Hematol. 1994;68 Suppl 3:S9-14. doi: 10.1007/BF01774523.
5
The manufacturing of the recombinant factor VIII, Kogenate.
Transfus Med Rev. 1992 Oct;6(4):256-60. doi: 10.1016/s0887-7963(92)70177-1.
6
Viral safety of B-domain deleted recombinant factor VIII.
Semin Hematol. 2001 Apr;38(2 Suppl 4):32-9. doi: 10.1016/s0037-1963(01)90106-4.
7
Recombinate antihaemophilic factor.
Dev Biol Stand. 1998;96:141-7.
8
Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.使用表面等离子体共振生物传感器筛选的抗凝血因子VIII单克隆抗体纯化重组人B结构域缺失的凝血因子VIII
Biotechnol Prog. 2001 Nov-Dec;17(6):1119-27. doi: 10.1021/bp010100o.
9
Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.生物技术与血浆分馏行业——凝血因子VIII生产进展的影响
Australas Biotechnol. 1993 Jan-Feb;3(1):16-20.
10
The manufacturing process for B-domain deleted recombinant factor VIII.
Semin Hematol. 2001 Apr;38(2 Suppl 4):24-31. doi: 10.1016/s0037-1963(01)90105-2.
Zotero 插件